Application Nr Approved Date Route Status External Links
ANDA077912 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Lisinopril And Hydrochlorothiazide Tablets Are Indicated For The Treatment Of Hypertension. These Fixed-Dose Combinations Are Not Indicated For Initial Therapy (see Dosage And Administration ). In Using Lisinopril And Hydrochlorothiazide Tablets, Consideration Should Be Given To The Fact That An Angiotensin Converting Enzyme Inhibitor, Captopril, Has Caused Agranulocytosis, Particularly In Patients With Renal Impairment Or Collagen Vascular Disease, And That Available Data Are Insufficient To Show That Lisinopril Does Not Have A Similar Risk. (see Warnings .) In Considering Use Of Lisinopril And Hydrochlorothiazide Tablets, It Should Be Noted That Black Patients Receiving Ace Inhibitors Have Been Reported To Have A Higher Incidence Of Angioedema Compared To Non-Blacks. (see Warnings, Head And Neck Angioedema .)

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Comments